ENTITY
Ivonescimab
Ivonescimab
PulseAugur coverage of Ivonescimab — every cluster mentioning Ivonescimab across labs, papers, and developer communities, ranked by signal.
Total · 30d
1
2 over 90d
Releases · 30d
0
0 over 90d
Papers · 30d
1
1 over 90d
TIER MIX · 90D
TOPICS
TIMELINE
- 2026-08-27 research_milestone Akeso's Ivonescimab demonstrated superior performance compared to AstraZeneca's Imfinzi in a Phase 3 trial for biliary tract cancer. source
SENTIMENT · 30D
1 day(s) with sentiment data
RECENT · PAGE 1/1 · 2 TOTAL
-
Akeso's Ivonescimab Outperforms AstraZeneca's Imfinzi in Cancer Trial
Chinese biopharmaceutical company Akeso announced that its immunotherapy drug, Ivonescimab, outperformed AstraZeneca's Imfinzi in a Phase 3 trial for biliary tract cancer. This trial, involving 682 patients, is the firs…
-
Akeso's lung cancer drug shows 34% reduced death risk in trials
Akeso's lung cancer drug, ivonescimab, has shown significant promise in phase three clinical trials, reducing the risk of death by 34%. The drug demonstrated a notable survival benefit, with 64.7% of patients alive afte…